BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1325@pharmaconomics
DTSTAMP:20260707T020128Z
DTSTART;VALUE=DATE:20251231
DTEND;VALUE=DATE:20260101
SUMMARY:PRTC Phase 2 — LYT-200
DESCRIPTION:Phase 2 trial results for LYT-200 in relapsed/refractory high-risk myelodysplastic syndrome are due Dec 31\, 2025. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1782999/000119312526188811/d38199dex991.htm\n\nTrack it: https://www.pharmaconomics.com/e/1325
URL:https://www.pharmaconomics.com/e/1325
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:PRTC catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR